Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders

Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p

Related Keywords

,Giulio Maria Pasinetti ,Daniell Alkon ,Maria Pasinetti ,Drug Administration ,Synaptogenix Inc ,International Association Of Biomedical Sciences ,Nasdaq ,University Of Southern ,Icahn School Of Medicine At Mount Sinai ,Exchange Commission ,Prnewswire Synaptogenix Inc ,Chief Scientific Officer ,International Association ,Biomedical Sciences ,Southern California Sponsored ,Neurodegenerative Disorders ,Saunders Family Chair ,Icahn School ,Mount Sinai ,National Neurologic Institute ,National Institutes ,Patients Show Safe ,Persistent Benefit ,Month Bryostatin Trial ,Orphan Drug Designation ,Markets ,